Wednesday, March 4, 2015

Treatment in Lupus Nephritis

Adjunctive Therapy
  • all SLE patients with nephritis be treated with a background of hydroxychloroquine (lower flare rates and lower renal damage)
  • All lupus nephritis patients with proteinuria ≥ 0.5 g per 24 hours should have blockade of the renin-angiotensin system, with ACEi or ARBs (reduces proteinuria approximately 30%, and significantly delays doubling of serum creatinine and progression to end stage )
  • Management of blood pressure and cholesterol (higher risk of atherosclerosis)
Treatment based on Classifications
  • Corticosteroid therapy should be instituted if the patient has clinically significant renal disease. 
  • Use immunosuppressive agents, particularly cyclophosphamide, azathioprine, or mycophenolate mofetil, if the patient has aggressive proliferative renal lesions, as they improve the renal outcome
Class I-II

  • requires no specific therapy
  • may require treatment if proteinuria is greater than 1000 mg/day. Consider prednisone in low-to-moderate doses (ie, 20-40 mg/day) for 1-3 months, with subsequent taper

Class III-IV

  • Mycophenolate mofetil was found to be superior to azathioprine in maintaining control and preventing relapses of lupus nephritis in patients who have responded to induction therapy




Class V:

Treatment at ESRD
  • Patients with ESRD require dialysis and are good candidates for kidney transplantation
  • Patients with end-stage renal disease (ESRD), sclerosis, and a high chronicity index based on renal biopsy findings are unlikely to respond to aggressive therapy. In these cases, focus therapy on extrarenal manifestations of systemic lupus erythematosus (SLE)

References:
1. http://emedicine.medscape.com/article/330369-treatment#aw2aab6b6b1aa
2. American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis



No comments:

Post a Comment

Note: Only a member of this blog may post a comment.